Taipei
Taiwan
hepatocellular carcinoma, liver cancer, nivolumab, PD-1 inhibitor, sorafenib, immuno-oncology, CheckMate
Phthalate, Breast cancer, Cohort study, Metabolism capability
Helicobacter pylori, MALT, DLBCL, Stomach, Response, Biomarkers
landmark analysis; lenvatinib; mRECIST; response status; surrogate endpoint